Alembic Pharmaceuticals Ltd.
NSE: APLLTD · Pharmaceuticals
Snapshot
Unlock Alembic Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alembic Pharmaceuticals Limited is a Vadodara-based company engaged in the development, manufacture, and marketing of pharmaceutical products. Its portfolio encompasses active pharmaceutical ingredients (APIs) and a diverse range of branded and generic formulations across multiple therapeutic areas.
Business Model
The company generates revenue through the sale of pharmaceutical formulations and APIs in both domestic and international markets. It leverages a broad therapeutic presence, including cardiology, anti-infectives, and anti-diabetics, to maintain market share.
- Founded:1907
Growth Outlook
Growth is driven by the expansion of its generic and branded formulation portfolios in international markets and the continued development of its API manufacturing capabilities.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and inspections by international health authorities like the USFDA.
- Pricing Pressure. Intense competition in the generic pharmaceutical market can lead to significant price erosion and margin compression.
- Currency Volatility. As an exporter, the company is exposed to fluctuations in foreign exchange rates which may impact profitability.
- Supply Chain Disruptions. Dependence on external suppliers for raw materials and APIs poses a risk to consistent manufacturing operations.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Alembic Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹7,345 Cr
TTM · consolidated
NET PROFIT
₹671 Cr
TTM · consolidated
EPS
₹34.32
TTM · consolidated
RETURN ON EQUITY
12.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
14.2%
TTM · consolidated
P/E
24.5x
Q4 FY26 · consolidated
EV/EBITDA
15.1x
Q4 FY26 · consolidated
EBITDA MARGIN
16.0%
TTM · consolidated
NET PROFIT MARGIN
10.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Alembic Pharmaceuticals Ltd.APLLTD | 13,129 | 24.47 | 15.07 | 10.1% | 16.0% | 12.6% | 14.2% | -18.1% |
Granules India Ltd.GRANULES | 14,432 | 36.96 | 18.95 | 19.7% | 22.5% | 14.7% | 19.6% | +80.8% |
Jubilant Pharmova Ltd.JUBLPHARMA | 13,858 | 40.58 | 13.67 | 14.4% | 16.0% | 6.1% | 7.4% | -14.6% |
Rubicon ResearchRUBICON | 12,884 | — | — | — | 23.0% | — | — | — |
Caplin Point Laboratories Ltd.CAPLIPOINT | 12,103 | 31.67 | 23.06 | 12.9% | 40.1% | 21.4% | 26.0% | +28.5% |
Alivus LifeALIVUS | 11,958 | 25.31 | 16.66 | 6.9% | 33.6% | 19.2% | 24.6% | +9.2% |
As of Q4 FY26
Financials
Alembic Pharmaceuticals Ltd.
NSE: APLLTD · Pharmaceuticals
Snapshot
Unlock Alembic Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alembic Pharmaceuticals Limited is a Vadodara-based company engaged in the development, manufacture, and marketing of pharmaceutical products. Its portfolio encompasses active pharmaceutical ingredients (APIs) and a diverse range of branded and generic formulations across multiple therapeutic areas.
Business Model
The company generates revenue through the sale of pharmaceutical formulations and APIs in both domestic and international markets. It leverages a broad therapeutic presence, including cardiology, anti-infectives, and anti-diabetics, to maintain market share.
- Founded:1907
Growth Outlook
Growth is driven by the expansion of its generic and branded formulation portfolios in international markets and the continued development of its API manufacturing capabilities.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and inspections by international health authorities like the USFDA.
- Pricing Pressure. Intense competition in the generic pharmaceutical market can lead to significant price erosion and margin compression.
- Currency Volatility. As an exporter, the company is exposed to fluctuations in foreign exchange rates which may impact profitability.
- Supply Chain Disruptions. Dependence on external suppliers for raw materials and APIs poses a risk to consistent manufacturing operations.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Alembic Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹7,345 Cr
TTM · consolidated
NET PROFIT
₹671 Cr
TTM · consolidated
EPS
₹34.32
TTM · consolidated
RETURN ON EQUITY
12.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
14.2%
TTM · consolidated
P/E
24.5x
Q4 FY26 · consolidated
EV/EBITDA
15.1x
Q4 FY26 · consolidated
EBITDA MARGIN
16.0%
TTM · consolidated
NET PROFIT MARGIN
10.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26